Resistance against novel anticancer metal compounds

differences and similarities

Petra Heffeter, Ute Jungwirth, Michael Jakupec, Christian Hartinger, Markus Galanski, Leonilla Elbling, Michael Micksche, Bernhard Keppler, Walter Berger

Research output: Contribution to journalReview article

168 Citations (Scopus)

Abstract

The platinum antitumor drugs cisplatin, carboplatin and oxaliplatin are widely used components of modern cancer chemotherapy. However, their success is limited by severe adverse effects and because of the impact of intrinsic and acquired resistance mechanisms on tumor responses. Consequently, intense efforts have been made to develop new metal compounds that either display enhanced tumor specificity or are less prone to the development of resistance. Despite the synthesis of thousands of compounds during the last decades only very few novel metal drugs have successfully reached clinical development and/or approval so far. In this review we summarize the current knowledge on drug resistance mechanisms against novel metal compounds (including platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum drugs), and address the question whether there might exist a general metal-drug resistance phenotype.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalDrug Resistance Updates
Volume11
Issue number1-2
DOIs
Publication statusPublished - 9 Apr 2008

Fingerprint

Metals
oxaliplatin
Drug Resistance
Platinum Compounds
Lanthanum
Neoplasms
Gallium
Ruthenium
Carboplatin
Arsenic
Titanium
Platinum
Pharmaceutical Preparations
Antineoplastic Agents
Cisplatin
Copper
Phenotype
Drug Therapy

Keywords

  • Animals
  • Antineoplastic Agents/chemistry
  • Cell Line, Tumor
  • Cell Survival/drug effects
  • Drug Resistance, Neoplasm/drug effects
  • Humans
  • Molecular Structure
  • Organometallic Compounds/chemistry
  • Structure-Activity Relationship

Cite this

Heffeter, P., Jungwirth, U., Jakupec, M., Hartinger, C., Galanski, M., Elbling, L., ... Berger, W. (2008). Resistance against novel anticancer metal compounds: differences and similarities. Drug Resistance Updates, 11(1-2), 1-16. https://doi.org/10.1016/j.drup.2008.02.002

Resistance against novel anticancer metal compounds : differences and similarities. / Heffeter, Petra; Jungwirth, Ute; Jakupec, Michael; Hartinger, Christian; Galanski, Markus; Elbling, Leonilla; Micksche, Michael; Keppler, Bernhard; Berger, Walter.

In: Drug Resistance Updates, Vol. 11, No. 1-2, 09.04.2008, p. 1-16.

Research output: Contribution to journalReview article

Heffeter, P, Jungwirth, U, Jakupec, M, Hartinger, C, Galanski, M, Elbling, L, Micksche, M, Keppler, B & Berger, W 2008, 'Resistance against novel anticancer metal compounds: differences and similarities', Drug Resistance Updates, vol. 11, no. 1-2, pp. 1-16. https://doi.org/10.1016/j.drup.2008.02.002
Heffeter, Petra ; Jungwirth, Ute ; Jakupec, Michael ; Hartinger, Christian ; Galanski, Markus ; Elbling, Leonilla ; Micksche, Michael ; Keppler, Bernhard ; Berger, Walter. / Resistance against novel anticancer metal compounds : differences and similarities. In: Drug Resistance Updates. 2008 ; Vol. 11, No. 1-2. pp. 1-16.
@article{3554ee2872d54b3bac43528bb9572882,
title = "Resistance against novel anticancer metal compounds: differences and similarities",
abstract = "The platinum antitumor drugs cisplatin, carboplatin and oxaliplatin are widely used components of modern cancer chemotherapy. However, their success is limited by severe adverse effects and because of the impact of intrinsic and acquired resistance mechanisms on tumor responses. Consequently, intense efforts have been made to develop new metal compounds that either display enhanced tumor specificity or are less prone to the development of resistance. Despite the synthesis of thousands of compounds during the last decades only very few novel metal drugs have successfully reached clinical development and/or approval so far. In this review we summarize the current knowledge on drug resistance mechanisms against novel metal compounds (including platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum drugs), and address the question whether there might exist a general metal-drug resistance phenotype.",
keywords = "Animals, Antineoplastic Agents/chemistry, Cell Line, Tumor, Cell Survival/drug effects, Drug Resistance, Neoplasm/drug effects, Humans, Molecular Structure, Organometallic Compounds/chemistry, Structure-Activity Relationship",
author = "Petra Heffeter and Ute Jungwirth and Michael Jakupec and Christian Hartinger and Markus Galanski and Leonilla Elbling and Michael Micksche and Bernhard Keppler and Walter Berger",
year = "2008",
month = "4",
day = "9",
doi = "10.1016/j.drup.2008.02.002",
language = "English",
volume = "11",
pages = "1--16",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Resistance against novel anticancer metal compounds

T2 - differences and similarities

AU - Heffeter, Petra

AU - Jungwirth, Ute

AU - Jakupec, Michael

AU - Hartinger, Christian

AU - Galanski, Markus

AU - Elbling, Leonilla

AU - Micksche, Michael

AU - Keppler, Bernhard

AU - Berger, Walter

PY - 2008/4/9

Y1 - 2008/4/9

N2 - The platinum antitumor drugs cisplatin, carboplatin and oxaliplatin are widely used components of modern cancer chemotherapy. However, their success is limited by severe adverse effects and because of the impact of intrinsic and acquired resistance mechanisms on tumor responses. Consequently, intense efforts have been made to develop new metal compounds that either display enhanced tumor specificity or are less prone to the development of resistance. Despite the synthesis of thousands of compounds during the last decades only very few novel metal drugs have successfully reached clinical development and/or approval so far. In this review we summarize the current knowledge on drug resistance mechanisms against novel metal compounds (including platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum drugs), and address the question whether there might exist a general metal-drug resistance phenotype.

AB - The platinum antitumor drugs cisplatin, carboplatin and oxaliplatin are widely used components of modern cancer chemotherapy. However, their success is limited by severe adverse effects and because of the impact of intrinsic and acquired resistance mechanisms on tumor responses. Consequently, intense efforts have been made to develop new metal compounds that either display enhanced tumor specificity or are less prone to the development of resistance. Despite the synthesis of thousands of compounds during the last decades only very few novel metal drugs have successfully reached clinical development and/or approval so far. In this review we summarize the current knowledge on drug resistance mechanisms against novel metal compounds (including platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum drugs), and address the question whether there might exist a general metal-drug resistance phenotype.

KW - Animals

KW - Antineoplastic Agents/chemistry

KW - Cell Line, Tumor

KW - Cell Survival/drug effects

KW - Drug Resistance, Neoplasm/drug effects

KW - Humans

KW - Molecular Structure

KW - Organometallic Compounds/chemistry

KW - Structure-Activity Relationship

U2 - 10.1016/j.drup.2008.02.002

DO - 10.1016/j.drup.2008.02.002

M3 - Review article

VL - 11

SP - 1

EP - 16

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 1-2

ER -